Adusumilli et al. reported the results of a phase I trial investigating the intrapleural delivery of mesothelin-targeted CAR T cells in patients with pleural cancer from malignant pleural mesothelioma, metastatic lung cancer, or breast cancer [113]. The gene discussed is MSLN; the disease is malignant pleural mesothelioma.